Logo image of TLSA

TIZIANA LIFE SCIENCES LTD (TLSA) Stock Fundamental Analysis

NASDAQ:TLSA - Nasdaq - BMG889121031 - Common Stock - Currency: USD

1.29  -0.07 (-5.15%)

After market: 1.28 -0.01 (-0.78%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TLSA. TLSA was compared to 566 industry peers in the Biotechnology industry. Both the profitability and financial health of TLSA have multiple concerns. TLSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TLSA had negative earnings in the past year.
TLSA had a negative operating cash flow in the past year.
In the past 5 years TLSA always reported negative net income.
TLSA had a negative operating cash flow in each of the past 5 years.
TLSA Yearly Net Income VS EBIT VS OCF VS FCFTLSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

The Return On Assets of TLSA (-125.21%) is worse than 81.10% of its industry peers.
With a Return On Equity value of -740.05%, TLSA is not doing good in the industry: 81.98% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -125.21%
ROE -740.05%
ROIC N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSA Yearly ROA, ROE, ROICTLSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K -1.5K

1.3 Margins

TLSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSA Yearly Profit, Operating, Gross MarginsTLSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for TLSA has been increased compared to 1 year ago.
The number of shares outstanding for TLSA has been increased compared to 5 years ago.
The debt/assets ratio for TLSA is higher compared to a year ago.
TLSA Yearly Shares OutstandingTLSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
TLSA Yearly Total Debt VS Total AssetsTLSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

TLSA has an Altman-Z score of 3.50. This indicates that TLSA is financially healthy and has little risk of bankruptcy at the moment.
TLSA has a better Altman-Z score (3.50) than 76.86% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that TLSA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, TLSA is in line with its industry, outperforming 41.70% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 3.5
ROIC/WACCN/A
WACCN/A
TLSA Yearly LT Debt VS Equity VS FCFTLSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

TLSA has a Current Ratio of 0.85. This is a bad value and indicates that TLSA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.85, TLSA is doing worse than 90.28% of the companies in the same industry.
A Quick Ratio of 0.85 indicates that TLSA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.85, TLSA is doing worse than 89.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.85
TLSA Yearly Current Assets VS Current LiabilitesTLSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.56% over the past year.
EPS 1Y (TTM)27.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.28% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.33%
EPS Next 2Y3.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TLSA Yearly Revenue VS EstimatesTLSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
TLSA Yearly EPS VS EstimatesTLSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TLSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSA Price Earnings VS Forward Price EarningsTLSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSA Per share dataTLSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.28%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TIZIANA LIFE SCIENCES LTD

NASDAQ:TLSA (5/1/2025, 9:33:20 PM)

After market: 1.28 -0.01 (-0.78%)

1.29

-0.07 (-5.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-11 2024-06-11/amc
Earnings (Next)N/A N/A
Inst Owners0.88%
Inst Owner Change0.11%
Ins Owners35.56%
Ins Owner ChangeN/A
Market Cap142.75M
Analysts82.86
Price TargetN/A
Short Float %1.47%
Short Ratio1.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 76.95
P/tB 76.95
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.21%
ROE -740.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.77%
ROA(5y)-135.3%
ROE(3y)-151.66%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.85
Altman-Z 3.5
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.5%
EPS Next Y13.33%
EPS Next 2Y3.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.07%
OCF growth 3YN/A
OCF growth 5YN/A